



# Biosergen's warrants of series TO2 are admitted to trading

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, CANADA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

**The rights issue of shares and warrants in Biosergen AB ("Biosergen" or the "Company") was registered at the Swedish Companies Registration Office on October 14, 2022. The warrants of series TO2 will be trading on Nasdaq First North Growth Market starting October 26, 2022, under the ticker "BIOSGN TO2" with ISIN-code SE0018588220.**

## **The warrants**

The warrants of series TO2 that was included in the rights issue of units in September 2022, have now been registered at the Swedish Companies Registration Office and the Company has received approval from Nasdaq for the warrants to be admitted to trading. First day of trading in the warrants of series TO2 has been set to October 26, 2022.

One (1) warrant of series TO2 entitles subscription of one (1) new share in the Company during the exercise period that runs from and including August 14 up to and including August 25, 2023. The subscription price for one (1) share will correspond to 70 percent of the volume weighted average price during the period from and including July 28 up to and including August 10, 2023. The subscription price can't be lower than the quota value of the Company's share or higher than SEK 4.5, meaning that the Company can raise a maximum of SEK 39 million through the warrants of series TO2.

## **Advisers**

Mangold Fondkommission AB is the financial adviser to Biosergen in connection with the Rights Issue. Advokatfirman Lindahl KB is the legal adviser to the Company in connection with the Rights Issue.

## **For further information about Biosergen, please contact:**

Dr. Peder M. Andersen, CEO

Telephone: +45 2080 2470

E-mail: [peder.andersen@biosergen.net](mailto:peder.andersen@biosergen.net)

## **Certified Adviser**

Erik Penser Bank

Telephone: +46 8 463 8000

E-mail: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

## **ABOUT BIOSERGEN**

Biosergen is a clinical stage biotechnology company that employs all its organisational and financials resources on the clinical development of BSG005. BSG005 is a potentially disruptive antifungal drug with blockbuster potential based on significant safety and potency advantages over competing antifungals, including Amphotericin B, in more than a decade of laboratory and preclinical studies. The research behind BSG005 and its unique properties has been documented in over 20 peer reviewed scientific papers. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS-, cancer- and transplant patients every year. At equal dose levels BSG005 shows a three-to-fourfold potency advantage against relevant fungal strains compared to current standards of care, while being completely free of the kidney toxicity hampering other drugs in its class. The Company is also developing BSG005 Nano where the drug is packed in special nano particles to specifically target the lung, often the first affected organ in an invasive fungal

infection. BSG005 Nano Oral is an extension of BSG005 Nano. An oral formulation would greatly increase the usefulness, particularly as a prophylactic and as home treatment after transplants or cancer treatment to prevent invasive fungal infection. Biosergen has received orphan drug status for BSG005 in the United States.

### **Important information**

Release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions according to law and people in those jurisdictions, in which this press release has been announced or distributed, should inform themselves of and follow such legal restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Biosergen in any jurisdiction. Invitation to the persons concerned to participate in the Rights Issue only took place through the EU growth prospectus which the Company published in connection with the Rights Issue.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. The information in this press release may not be announced, published or distributed in or into the United Kingdom, the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Switzerland, South Africa or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.

Within the European Economic Area, no offer is made to the public of securities in any country other than Sweden. In other Member States of the European Union, such an offer may only be made in accordance with the exceptions in the Prospectus Regulation (EU) 2017/1129.

This press release contains certain forward-looking information that reflects the Company's present view of future events as well as financial and operational development. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development, and actual outcomes may differ materially from the statements set forth in the forward-looking information.